OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Market Closed - Deutsche Boerse AG 03:35:53 2024-06-07 pm EDT | ||
| 5.43 EUR | -0.73% |
|
| Current month | +9.04% | ||
| 1 month | +9.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 5.43 | -0.73% |
| 24-06-06 | 5.47 | +1.30% |
| 24-06-05 | 5.4 | +2.27% |
| 24-06-04 | 5.28 | +1.73% |
| 24-06-03 | 5.19 | +4.22% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD7J7P |
| ISIN | DE000SD7J7P7 |
| Date issued | 2021-04-14 |
| Strike | 7,948 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.62 € |
|---|---|
| Lowest since issue | 0.42 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
